Current Report Filing (8-k)
28 4월 2023 - 5:11AM
Edgar (US Regulatory)
0001718500
false
0001718500
2023-04-21
2023-04-21
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): April
21, 2023
REVIV3 PROCARE COMPANY
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-38112 |
|
43-1985966 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
|
|
|
|
|
901
Fremont Avenue, Unit 158 and Unit
168, Alhambra, CA |
|
91803 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (888) 638-8883
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
None |
N/A |
N/A |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
| Item
5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment
of Certain Officers; Compensatory Arrangements of Certain Officers. |
On April 21, 2023, Meenu Jain notified Reviv3 Procare Company (the “Company”)
that she will be stepping down as Chief Financial Officer of the Company effective at 4:00 p.m. (Pacific Time) on April 21, 2023, for
personal reasons. Ms. Jain’s resignation is not as a result of any disagreement with the Company on any matter relating to its operations,
policies, or practices, or to any issues regarding its accounting policies or practices.
On April 24, 2023, the Company appointed Monica Diaz Brickell, aged 44,
to serve as the Company’s Chief Financial Officer. Ms. Diaz Brickell will also serve as the Company’s principal accounting
officer and principal financial officer for purposes of the rules and regulations of the Securities and Exchange Commission.
Ms. Diaz Brickell has spent over twenty years serving in finance roles
at global, publicly traded companies, including as International Tax manager for Top Golf Callaway Brands Corp. and Senior Tax Associate
at Thermo Fisher Scientific. Ms. Diaz Brickell earned a Master of Science in Accountancy and a Bachelor of Business Administration in
Accounting from the University of Notre Dame and is an active Certified Public Accountant in the state of California.
The Company and Ms. Diaz Brickell entered into an employment agreement,
effective as of April 24, 2023 (the “Employment Agreement”), pursuant to which Ms. Diaz Brickell agreed to serve as the Company’s
Chief Financial Officer. Subject to other customary terms and conditions of such agreement, the Employment Agreement provides that Ms.
Diaz Brickell will receive a base salary of $140,000 per year, subject to annual review and adjustment. The Employment Agreement provides
that Ms. Diaz Brickell’s employment is “at will,” and either party may terminate her employment at any time and for
any reason, with or without cause. The Employment Agreement also includes customary confidentiality and assignment of inventions provisions,
as well as non-competition and non-solicitation restrictions.
The description of the Employment Agreement contained herein does not
purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Employment Agreement, a
copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. In addition to her
base salary, the Company intends to grant Ms. Diaz Brickell an equity award equivalent to 30,000 shares of common stock, subject to certain
performance and time vesting conditions.
To the Company’s
knowledge, there are no arrangements or understandings between Ms. Diaz Brickell and any other person pursuant to which she was
selected for her position. In addition, there are no family relationships between Ms. Diaz Brickell and any directors or executive
officers of the Company, and no transactions are required to be reported under Item 404(a) of Regulation S-K between Ms. Diaz
Brickell and the Company.
A copy of the press release
announcing Ms. Jain’s resignation and Ms. Diaz Brickell’s appointment is attached as Exhibit 99.1 to this Current Report
on Form 8-K. The press release is being furnished and the information included therein shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to
the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the
Securities Act of 1933, as amended, or the Exchange Act.
| Item
9.01 | Financial
Statements and Exhibits |
*
Management contract or compensatory plan or arrangement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
REVIV3
PROCARE COMPANY |
Date:
April 27, 2023 |
|
|
By: |
/s/ Jeff
Toghraie |
|
Name: |
Jeff
Toghraie |
|
Title: |
Chief Executive Officer |
|
|
|
Reviv3 Procare (QB) (USOTC:RVIV)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Reviv3 Procare (QB) (USOTC:RVIV)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Reviv3 Procare Company (QB) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Reviv3 Procare Co News Articles